Vitamins A and E: Vision, Retinoids and the Toxicity Trap

Why fat-soluble is a different rulebook

The chemistry that lets these vitamins be stored is the same chemistry that lets them accumulate to harm. There are only four fat-soluble vitamins — A, D, E and K — and they share a way of life. They are absorbed with dietary fat in the small intestine, packaged into chylomicrons, and carried to the liver, which stores them (the liver holds enough vitamin A for months). Because the body hoards rather than excretes them, two consequences follow. First, deficiency tends to appear where fat absorption fails — cholestasis, pancreatic insufficiency, coeliac disease, cystic fibrosis, or the loss of bile — a link explored in the Gastrointestinal section on fat malabsorption. Second, and the theme of this chapter, excess is not harmlessly flushed away; it builds up and can become toxic. Contrast this with the water-soluble vitamins, where a surplus mostly leaves in the urine. With A, D, E and K, more is not automatically better — and for two of them, more can be dangerous.

Vitamin A: one molecule, four jobs

Vitamin A is not a single compound but a family — retinol, its aldehyde retinal, and the acid retinoic acid, collectively the retinoids — plus the plant precursor beta-carotene the body can convert. It earns its keep in four ways. Vision: in the retina, retinal binds the protein opsin to form rhodopsin, the light-sensitive pigment of the rod cells that lets you see in dim light; a photon literally bends the retinal and triggers the signal. Epithelial and mucosal integrity: retinoic acid keeps the surface linings — cornea, airway, gut, skin — healthy and properly differentiated. Immune function: it supports mucosal barriers and immune cell responses, which is why deficiency worsens infection. And growth and differentiation: retinoic acid is a hormone-like signal, binding nuclear receptors (RAR and RXR) to switch genes on and off and steer cells toward their mature identity. Hold on to that last one — it is the key to both the therapeutic retinoids and the birth defects.

Deficiency: the leading preventable childhood blindness

Vitamin A deficiency follows a grim, predictable staircase — and each step down is preventable. The earliest sign is night blindness, as the rods run short of rhodopsin. Next the drying dominates: xerophthalmia, in which the conjunctiva and cornea lose their moist, healthy epithelium. On the conjunctiva appear Bitot's spots — foamy grey plaques of keratinized debris. If the deficiency continues, the cornea itself softens and breaks down: keratomalacia, with ulceration that can perforate and destroy the eye within days. This is one of the leading causes of preventable childhood blindness worldwide. But the damage is not confined to the eye. Because vitamin A guards epithelial barriers and immune defence, deficient children get more — and more lethal — infections; vitamin A deficiency markedly raises mortality from measles and diarrhoeal disease. This is why WHO high-dose vitamin A supplementation programmes target preschool children in at-risk regions, and why vitamin A is a standard part of treating measles in deficient children. A single cheap capsule reverses night blindness, protects the cornea, and saves lives.

Therapeutic retinoids: turning a vitamin into a drug

Because retinoic acid tells cells how to differentiate, engineered retinoids can be aimed at skin and even at cancer. The differentiation signal that makes vitamin A essential also makes it a drug scaffold. In dermatology, isotretinoin — an oral retinoid — is the most effective treatment for severe nodulocystic acne, shrinking sebaceous glands and normalizing the follicular lining; acitretin, another oral retinoid, is used for severe psoriasis. These agents, and the pregnancy rules that come with them, are covered in depth in the Dermatology section. In oncology comes the most elegant use of all: all-trans retinoic acid (ATRA, tretinoin) in acute promyelocytic leukaemia (APL). APL is a cancer of cells frozen at the promyelocyte stage, unable to mature. ATRA does not poison them like classical chemotherapy — it forces them to finish differentiating into harmless mature cells that then die naturally. This differentiation therapy, often combined with arsenic trioxide, turned APL from one of the most lethal leukaemias into one of the most curable, and is discussed in the Oncology section. Bexarotene, an RXR-selective retinoid, is used in cutaneous T-cell lymphoma. From a spot cream to a leukaemia cure, all of it flows from one idea: retinoids tell cells what to become.

The toxicity trap — the exam favourite

Because it is stored, not excreted, vitamin A poisons in overdose — this is hypervitaminosis A. Acute toxicity (a huge single dose — classically polar-bear or seal liver, or a swallowed bottle of supplements) causes headache, nausea and vomiting, and raised intracranial pressure with blurred vision and papilloedema. Chronic toxicity, from months of excess supplements or retinoid therapy, is a multi-system picture: dry, peeling skin and cracked lips, hair loss, painful bones and joints, hepatotoxicity that can progress to cirrhosis, and hypercalcaemia — a feature it shares with vitamin D toxicity, discussed in the Vitamin D chapter. But the single most important adverse effect, the one that dominates prescribing, is teratogenicity. Retinoids are among the most powerful human teratogens known: in pregnancy they cause severe craniofacial, cardiac and central-nervous-system malformations. This is why isotretinoin and acitretin are dispensed only under strict pregnancy-prevention programmes — mandatory contraception, pregnancy testing before, during and after, and a waiting period after stopping (long for isotretinoin, and years for the slowly-cleared acitretin). It is also why pregnant women are warned against high-dose vitamin A supplements and even against eating liver, which is extraordinarily rich in retinol. The rule to carry away: with vitamin A, the therapeutic window is real and the greatest danger is to a fetus.

Beta-carotene and the smoker's paradox

Beta-carotene, the orange pigment of carrots and leafy greens, is pro-vitamin A — the body converts it to retinol as needed, and this conversion is regulated, so dietary beta-carotene does not cause vitamin A toxicity (very high intake just tints the skin harmlessly). That safety made it a natural candidate for an antioxidant supplement — until two large trials delivered a shock. In heavy smokers and asbestos-exposed workers, high-dose beta-carotene supplements increased the incidence of lung cancer rather than preventing it. The supposed antioxidant behaved as a pro-carcinogen in already-damaged lung tissue. That signal has a direct downstream consequence in ophthalmology: the AREDS formula for age-related macular degeneration originally contained beta-carotene, and the follow-up AREDS2 formulation deliberately removed it — replacing it with lutein and zeaxanthin — specifically so it could be given safely to smokers. It is a cautionary tale told again in the Ophthalmology section, and a preview of the vitamin E story: an antioxidant that looked obviously good in theory did harm in practice.

Vitamin E: the membrane's antioxidant

Vitamin E's whole job is to take a hit so that the fats in your cell membranes don't. Vitamin E (tocopherol) is the body's main fat-phase antioxidant. Cell membranes are built from polyunsaturated fatty acids, which are exactly the molecules most vulnerable to attack by free radicals — a chain reaction called lipid peroxidation that would otherwise shred the membrane. Vitamin E, embedded in the membrane, intercepts those radicals and neutralizes them, sacrificing itself to break the chain; it is especially important in protecting red-cell and nerve membranes. Deficiency is rare, because the vitamin is widespread in the diet, and it appears essentially only where fat absorption fails badly — chronic cholestasis, cystic fibrosis, or the genetic disorder abetalipoproteinaemia, in which fat-carrying lipoproteins cannot be assembled. When it does occur, deficiency produces a neurological and haematological picture: a spinocerebellar ataxia with loss of coordination, peripheral neuropathy with lost reflexes and proprioception, and haemolysis as unprotected red-cell membranes break down. The neurology reflects vitamin E's role in shielding nerve membranes; the haemolysis reflects its role in the red cell.

The more clinically useful lesson about vitamin E in 2026, though, is not its deficiency but its supplements. Because it is an antioxidant, vitamin E was once hoped to prevent heart disease, cancer and dementia, and millions took high-dose capsules on that promise. Large trials and meta-analyses dismantled the hope: high-dose vitamin E confers no proven benefit for cardiovascular disease or cancer prevention, and at high doses it may modestly increase all-cause mortality and, by interfering with vitamin-K-dependent clotting, raise the risk of bleeding (including haemorrhagic stroke). This is the same moral as beta-carotene and the smokers: the intuitive idea that mopping up free radicals with megadose antioxidants must be healthy has repeatedly failed when tested. Correcting a genuine deficiency helps; supplementing beyond need does not, and can quietly harm.